10-K: Bio Essence Corp. Reports Full Year 2023 Results, Navigates Financial Challenges

Bio Essence Corp. reports a net loss of $971,879 for 2023, impacted by decreased sales and increased operating expenses, while also selling a subsidiary for $300,000.

Summary

• Bio Essence Corp. reported a net loss of $971,879 for the year ended December 31, 2023, compared to a net loss of $809,679 in 2022.
• The company's revenue decreased by 11.27% to $551,506 in 2023 from $621,590 in 2022, primarily due to decreased sales of goods and reduced shipping income.
• The cost of goods sold decreased by 6.55% to $274,060 in 2023, while the gross profit decreased by 15.50% to $277,446.
• Operating expenses increased by 27.04% to $1,066,496 in 2023, driven by higher selling and general and administrative expenses.
• The company sold its subsidiary, Bio Essence Pharmaceutical Inc. (BEP), for $300,000, resulting in a gain of $67,451.
• Bio Essence had a working capital deficit of $2,079,098 and a current ratio of 0.35:1 as of December 31, 2023.
• The company's cash and equivalents were $114 as of December 31, 2023, and it had a bank overdraft of $14,866.
• The company has significant debt, including $1,822,677 in loans from shareholders, and is dependent on these loans for funding.
• Management believes it needs $1.2 million in cash to continue operations for the next 12 months and is exploring options for additional financing.
• The company has a new operating lease for its facility with monthly rent of approximately $47,100 and a 3% annual increase.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges, including substantial losses, declining revenue, and a precarious liquidity position. While there are some positive aspects, such as the sale of a subsidiary, the overall sentiment is negative due to the company's financial instability and dependence on shareholder loans.

Positives

• The company generated a gain of $67,451 from the sale of its subsidiary, BEP.
• The company is actively exploring options to secure additional financing.
• The company has a new operating lease for its facility, securing its operational space.

Negatives

• The company experienced a significant net loss of $971,879 in 2023.
• Sales decreased by 11.27% year-over-year.
• Operating expenses increased by 27.04% in 2023.
• The company has a substantial working capital deficit of $2,079,098.
• The company's cash and equivalents are very low at $114.
• The company is heavily reliant on loans from shareholders for funding.
• The company has a current ratio of 0.35:1, indicating potential liquidity issues.

Risks

• The company's ability to continue as a going concern is in doubt due to recurring losses and negative cash flows.
• The company is heavily reliant on loans from a major shareholder, which are unsecured and payable on demand.
• The company may not be able to secure additional financing on acceptable terms or at all.
• The company's low cash balance and working capital deficit pose significant liquidity risks.
• The company's ability to increase sales and improve profitability is uncertain.
• The company's new lease agreement increases its financial obligations.

Future Outlook

The company plans to increase income by strengthening its sales force, providing attractive sales incentive programs, and increasing marketing and promotion activities. Management also intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others. The company believes it needs $1.2 million in cash to continue operations for the next 12 months.

Management Comments

• Management believes in the viability of its strategy to generate sufficient revenue.
• Management intends to raise additional funds by way of a private or public offering, or by obtaining loans from banks or others.
• Management concluded that, as of December 31, 2023, our internal controls over financial reporting were effective at the reasonable assurance level based on those criteria.

Industry Context

The company operates in the herbal health, diet, and nutrition supplement industry, which is competitive and subject to changing consumer preferences and regulatory requirements. The company's financial challenges reflect the difficulties faced by smaller companies in this sector, particularly in maintaining profitability and securing adequate funding.

Comparison to Industry Standards

• Bio Essence's financial performance, particularly its net loss and low cash reserves, is significantly below industry benchmarks for established companies in the health supplement sector.
• Companies like Herbalife and Nature's Bounty, which are larger and more established, typically have higher revenue, better profitability, and stronger balance sheets.
• Smaller companies in the sector often struggle with profitability and cash flow, but Bio Essence's current financial position is particularly precarious.
• The company's reliance on shareholder loans is not typical for established companies in the industry, which usually have access to more conventional financing options.
• The sale of the BEP subsidiary for $300,000 is a relatively small transaction compared to the overall financial needs of the company.

Related Party Transactions

• The company had loans from one major shareholder (also the company's senior officer) of $1,214,046 and $2,543,155 at December 31, 2023 and 2022, respectively.
• The company had a loan from another major shareholder for $608,631 for settling litigation at December 31, 2023 and 2022.
• On May 31, 2023, the Board of Directors approved a debt-to-equity conversion, where Ms. Yan received 5,000,000 shares in exchange for retiring $2,500,000 in debt.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future capital raises.
• Employees may be concerned about job security due to the company's financial challenges.
• Customers may experience disruptions if the company's financial issues impact its operations.
• Suppliers may face increased credit risk due to the company's financial difficulties.
• Creditors face increased risk of non-payment due to the company's low cash reserves and high debt.

Next Steps

• The company intends to strengthen its sales force and increase marketing activities.
• The company plans to explore options for additional financing, including private or public offerings.
• The company will continue to implement its business plan to generate sufficient revenue.

Key Dates

Keywords

financial results, net loss, revenue, operating expenses, working capital, liquidity, debt, loans, subsidiary sale, lease, going concern, herbal supplements, health supplements